login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock News
USA
- NASDAQ:ZNTL -
US98943L1070
-
Common Stock
1.58
USD
-0.13 (-7.6%)
Last: 10/29/2025, 10:16:06 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ZNTL Latest News, Press Relases and Analysis
All
Press Releases
16 days ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
a month ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
3 months ago - By: The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70%
4 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
6 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
7 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: Benzinga
- Mentions:
APDN
PRPH
IBO
SILO
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
7 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
7 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
8 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
8 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
8 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
9 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
9 months ago - By: Benzinga
- Mentions:
NBY
AZTR
OGEN
XNCR
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
9 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
9 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
9 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
10 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
10 months ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a year ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Key Management Appointments
a year ago - By: Kuehn Law, PLLC
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
a year ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a year ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a year ago - By: Kuehn Law, PLLC
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
a year ago - By: ZENTALIS PHARMACEUTICALS
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
Please enable JavaScript to continue using this application.